

ISUOG Practice Guidelines (updated): performance of the routine mid-trimester fetal ultrasound scan

Clinical Standards Committee

The International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) is a scientific organization that encourages sound clinical practice, and high-quality teaching and research related to diagnostic imaging in women's healthcare. The ISUOG Clinical Standards Committee (CSC) has a remit to develop Practice Guidelines and Consensus Statements as educational recommendations that provide healthcare practitioners with a consensus-based approach, from experts, for diagnostic imaging. They are intended to reflect what is considered by ISUOG to be the best practice at the time at which they are issued. Although ISUOG has made every effort to ensure that Guidelines are accurate when issued, neither the Society nor any of its employees or members accepts liability for the consequences of any inaccurate or misleading data, opinions or statements issued by the CSC. The ISUOG CSC documents are not intended to establish a legal standard of care, because interpretation of the evidence that underpins the Guidelines may be influenced by individual circumstances, local protocol and available resources. Approved Guidelines can be distributed freely with the permission of ISUOG (info@isuog.org).

INTRODUCTION

Ultrasonography is used widely for the prenatal evaluation of fetal growth and anatomy, as well as for the management of multiple gestations. The mid-trimester ultrasound scan is performed mainly for anatomical evaluation of the fetus. In experts' hands, most clinically important structural anomalies can be detected¹. However, there are significant differences in detection rates between centers and between operators. The mid-trimester fetal ultrasound scan also serves as a baseline against which later scans can be compared for the evaluation of fetal growth.

Although many countries have developed local guidelines for the practice of fetal ultrasonography, there are still many areas of the world where they have not been implemented. Most countries offer one mid-trimester scan as part of routine prenatal care. This document, which constitutes an updated version of previously published

guidelines², suggests the standards that this scan should aim to achieve. Details of the grades of recommendation and levels of evidence used in ISUOG Guidelines are given in Appendix 1.

GENERAL CONSIDERATIONS

Before starting the examination, a healthcare practitioner should counsel the woman/couple regarding the potential benefits and limitations of a routine mid-trimester fetal ultrasound scan.

A routine mid-trimester fetal ultrasound examination includes an evaluation of the following:

- cardiac activity;
- fetal number (and chorionicity and amnionicity in cases of multiple pregnancy);
- gestational age/fetal size;
- basic fetal anatomy;
- placental appearance and location;
- amniotic fluid volume.

In some settings, measurement of cervical length (CL) is offered to women at the time of the mid-trimester scan within the context of prediction and prevention of preterm birth. A current suggestion is that CL measurements should be done by transvaginal scanning, which requires additional consent from the woman, appropriate training of the operator³ and auditing of the results. When CL measurement can be carried out meeting these conditions, it can be considered as an integral part of the routine mid-trimester scan. The 'ISUOG Practice Guidelines: role of ultrasound in the prediction of spontaneous preterm birth' (in prep.) will provide more guidance and details.

When uterine and adnexal masses (fibroids, ovarian cysts) are visualized, they should be reported, but formal assessment of uterine and adnexal anatomy is not part of the routine mid-trimester scan.

Although many fetal malformations and anomalies can be identified at this mid-trimester scan, some may be missed or may become apparent only later in pregnancy, even with the best sonographic equipment in the best of hands.

Who should have a mid-trimester fetal ultrasound scan?

Recommendation

- All pregnant women should be offered a mid-trimester scan as part of routine pregnancy care (**GRADE OF RECOMMENDATION: B**).

All pregnant women should be offered a mid-trimester scan as part of routine pregnancy care. In many settings, it is customary to perform a routine first-trimester scan to assess viability and pregnancy location, for accurate dating of the pregnancy, for assessment of chorionicity in multiple pregnancy and to evaluate the uterus and adnexa for anomalies that may affect pregnancy management⁴. If the first-trimester scan is normal, then a standard mid-trimester scan should still be offered, to check for anomalies that may not have been evident in early pregnancy. A 2005 cost-effectiveness analysis concluded that strategies which include a mid-trimester ultrasound scan result in more abnormalities being detected and have lower costs per anomaly detected⁵. It is likely that this policy has become even more effective since then, as the detection rate of congenital heart defects may have increased⁶. If anomalies are seen or suspected at the first-trimester scan, the patient should be referred promptly for expert evaluation and counseling, without awaiting the mid-trimester scan. Thereafter, subsequent detailed scans can be performed as needed.

When should the mid-trimester fetal ultrasound scan be performed?

Recommendation

- A routine mid-trimester ultrasound scan can be performed between about 18 and 24 weeks of gestation, depending on technical considerations and local legislation (**GOOD PRACTICE POINT**).

A routine mid-trimester ultrasound scan is usually performed between about 18 and 24 weeks of gestation. This may be adjusted according to technical considerations, including high body mass index. Countries in which pregnancy termination is restricted by gestational age should balance detection rates against the time needed for counseling and additional investigation.

Who should perform the mid-trimester fetal ultrasound scan?

Recommendation

- Individuals who perform obstetric scans routinely should have been trained for the practice of diagnostic ultrasonography in pregnant women (**GOOD PRACTICE POINT**).

Individuals who perform obstetric scans routinely should have been trained for the practice of diagnostic

ultrasonography in pregnant women. Local regulations should be followed for training, maintenance of skills and certification, as these vary between jurisdictions⁷. Simulation training may also be considered⁸.

In order to achieve optimal results from routine screening examinations, scans should be performed by individuals who fulfill the following criteria:

- trained in the use of diagnostic ultrasonography and related safety issues;
- regularly perform fetal ultrasound scans;
- participate in continuing medical education activities;
- have established appropriate referral patterns for management of suspicious or abnormal findings;
- routinely undertake quality assurance and control measures.

What ultrasonographic equipment should be used?

For routine screening, equipment should have at least the following:

- real-time, grayscale ultrasound capabilities;
- transabdominal transducers with suitable resolution and penetration (usually 2–9-MHz range);
- adjustable acoustic power output controls with output display on the screen;
- freeze-frame capability;
- electronic calipers;
- capacity to print/store images;
- regular maintenance and servicing, important for optimal equipment performance;
- suitable cleaning equipment and cleaning protocols;
- color and pulsed Doppler are desirable;
- transvaginal probes are desirable.

What document should be produced/stored/printed or sent to the referring healthcare provider?

Recommendation

- The results of the scan should be documented and communicated appropriately, and copies of the reports and images should be stored for future reference (**GOOD PRACTICE POINT**).

The report of the examination should be produced and forwarded promptly to the referring care provider. Its content should follow local practice and regulations. A sample form is appended to these Guidelines (Appendix 2), and may be modified as appropriate. Standard practice on how to communicate with the pregnant woman before and during the scan and how to provide the results should be established. Generally, any significant concerning findings should be communicated promptly and separately to the care provider to facilitate appropriate patient care. It is reasonable to include recommendations for further management if the person performing the scan is entitled to do so and prompt

referral should be organized when indicated. Reports may be electronic or on paper. The number of images produced will vary according to local protocols. It is strongly suggested that both reports and images are stored so they are easily and rapidly accessible for review or transmission, and they are archived following local guidelines and regulations.

Is prenatal ultrasonography safe?

Recommendation

- Prenatal ultrasonography appears to be safe in clinical practice; however, it should follow the ALARA principle and not be performed solely for parental entertainment purposes (**GOOD PRACTICE POINT**).

Prenatal ultrasonography appears to be safe in clinical practice. To date, there has been no independently confirmed study to suggest otherwise. Nonetheless, fetal exposure times should be minimized, using the lowest possible power output needed to obtain diagnostic information, following the ALARA principle (As Low As Reasonably Achievable)⁹. More details are available in the ISUOG Safety Statement¹⁰. Equipment, probes and gels should be treated appropriately to provide a safe environment for patients and staff. Although prenatal ultrasonography can provide beautiful souvenir images of the fetus, it should not be performed solely for entertainment purposes¹⁰.

What if the examination cannot be performed in accordance with these Guidelines?

Recommendation

- If the examination cannot be performed completely in accordance with adopted guidelines, the scan should be repeated to ensure a complete examination, or the patient should be referred to another examiner (**GRADE OF RECOMMENDATION: C**).

These recommendations represent minimum suggested Practice Guidelines for the mid-trimester fetal ultrasound scan. If time, equipment and skills allow, more comprehensive evaluation is encouraged. Consideration should be given to local circumstances, standard practice and regulations. Reasons for deviations from these recommendations should be documented. If the examination cannot be performed completely in accordance with adopted guidelines, the scan should be repeated to ensure a complete examination, or the patient should be referred to another examiner, as abnormalities are eventually detected in 0.5–5% of such cases^{11,12}. This should be done as soon as possible, to minimize unnecessary patient anxiety and unnecessary delay in the potential diagnosis of congenital anomalies or growth disturbances.

What is the role of a more targeted ultrasonographic examination?

These Guidelines refer to routine ultrasound evaluation of pregnant women who have no maternal, fetal or obstetric risk factors. Even if risk factors are present, it is still appropriate to consider a mid-trimester scan following these Guidelines, for baseline pregnancy evaluation. Additional, more comprehensive, detailed ultrasonographic examinations in response to specific clinical situations should be performed to address specific needs. These are best performed by specialists experienced in such comprehensive evaluations, and are beyond the scope of these general Guidelines.

Individuals or clinics performing routine ultrasonographic scans during pregnancy should have referral mechanisms in place to manage suspected or detected anomalies. A complete screening examination according to the Guidelines presented here should still be performed before referring a woman, unless technical factors prevent completion of the initial evaluation.

GUIDELINES FOR EXAMINATION

Fetal biometry and wellbeing

Recommendations

- The biparietal diameter (BPD), head circumference (HC), abdominal circumference (AC) and femur length (FL) can be measured routinely for the assessment of fetal size (**GOOD PRACTICE POINT**).
- If the fetus has not been dated previously, HC or HC plus FL can be used for dating after 14 weeks (**GRADE OF RECOMMENDATION: B**).

The following sonographic parameters can be measured routinely for assessment of fetal size^{13,14}:

- biparietal diameter (BPD);
- head circumference (HC);
- abdominal circumference (AC);
- femur length (FL).

Measurements should be performed in a standardized manner on the basis of strict quality criteria^{15–17} and in accordance with ISUOG Practice Guidelines¹³. An image should be obtained to document each measurement. Examples of still images appropriate for fetal biometry are demonstrated in Figure 1. An audit of results can help to ensure accuracy of techniques with regard to specific reference tables^{16,18}.

A first-trimester ultrasound examination should have been offered routinely⁴, allowing exact gestational-age assessment. If gestational age has not already been established at a dating or first-trimester scan, it should be determined at the mid-trimester scan. Although head measurements (BPD and HC) and FL have all been used in the past, recent evidence from the INTERGROWTH-21st study indicates that HC alone or HC plus FL may be




Figure 1 Standard fetal biometry. Sonographic measurements of: (a) head circumference (HC), (b) abdominal circumference (AC) and (c) femur length (FL).

the most accurate predictor of gestational age after 14 weeks¹⁹. Subsequent scans should not be used to calculate a new estimated date of confinement if gestational age has already been established by a high-quality scan earlier in the pregnancy.

Biparietal diameter (BPD)

Recommendation

- Outer-to-outer placement of calipers is preferable when measuring BPD (**GOOD PRACTICE POINT**).

Anatomy. The following anatomical landmarks ensure optimal acquisition of the imaging plane for measurement of BPD.

- Transverse view of the fetal head at the level of the thalami;
- ideal angle of insonation is 90° to the midline echoes, but slight variations are permitted;
- symmetrical appearance of both hemispheres;
- midline echo (falx cerebri) interrupted anteriorly only by the cavum septi pellucidi;
- cerebellum not visible.

Caliper placement. Both calipers should be placed according to a specific methodology, because more than one technique has been described (e.g. outer-to-inner edge ('leading edge' technique) *vs* outer-to-outer edge), at the widest part of the skull, perpendicular to the midline. The same technique as that used to establish the reference chart should be used. The cephalic index is a ratio of the maximum head width (BPD) to its maximum length (occipitofrontal diameter (OFD)) and this value can be used to characterize the fetal head shape. Abnormal head shape (e.g. brachycephaly or dolichocephaly) can be associated with syndromes or be the result of oligohydramnios or breech presentation. This finding can also lead to inaccurate estimates of fetal age when the BPD is used; in these cases, HC measurements are even more reliable^{20,21}. Recent evidence suggests that outer-to-outer placement of calipers eases standardization, reproducibility and quality control²².

Head circumference (HC)

Recommendations

- HC can either be measured using the ellipse approach, or derived from BPD and OFD (**GOOD PRACTICE POINT**).
- Outer-to-outer placement of calipers is preferable when measuring HC (**GRADE OF RECOMMENDATION: C**).

Anatomy. The same anatomical landmarks as those for BPD should be used.

Caliper placement. As for the BPD, it is important to ensure that the HC placement markers correspond to those used for the reference chart. If the ultrasound equipment has ellipse measurement capacity, the HC can be measured directly by placing the ellipse around the outside of the skull bone echoes (Figure 1a). Alternatively, the HC can be calculated from the BPD and OFD as follows: the BPD is measured using a leading-edge technique, as described in the 'Biparietal diameter' section, above, whereas the OFD is obtained by placing the calipers in the middle of the bone echo at both the frontal and occipital skull bones. HC is then calculated as $HC = 1.62 \times (BPD + OFD)$. Recent evidence suggests that outer-to-outer placement of calipers eases standardization, reproducibility and quality control²².

Abdominal circumference (AC)

Recommendations

- For the measurement of AC, the transverse section of the fetal abdomen should be as circular as possible, and the fetal spine preferably in the 3- or 9-o'clock position (**GOOD PRACTICE POINT**).
- AC can either be measured using the ellipse approach, or derived from anteroposterior and transverse abdominal diameters (**GOOD PRACTICE POINT**).

Anatomy. The following anatomical landmarks ensure optimal acquisition of the imaging plane for measurement of AC.

- Transverse section of the fetal abdomen (as circular as possible);
- umbilical vein at the level of the portal sinus;
- stomach visible;
- kidneys not visible.

Caliper placement. The AC is either measured directly at the outer surface of the skin line, with ellipse calipers (Figure 1b), or calculated from linear measurements made perpendicular to each other, usually the anteroposterior abdominal diameter (APAD) and the transverse abdominal diameter (TAD). To measure the APAD, the calipers are placed on the outer borders of the body outline, from the posterior aspect (skin covering the spine) to the anterior abdominal wall. To measure the TAD, the calipers are placed on the outer borders of the body outline, across the abdomen at the widest point. The AC is then calculated as $AC = 1.57 \times (APAD + TAD)$.

Femur length (FL)

Anatomy. The FL is imaged with both ends of the ossified diaphysis visible. The longest axis of the ossified diaphysis is measured. The same technique as that used to establish the reference chart should be used with regard to the angle between the femur and the insonating ultrasound beam. An angle of insonation between 45° and 90° is typical. Technical improvements in modern ultrasound machines have reduced the beam width, which has affected fetal measurements in the lateral direction²³. This has clinical implications and recent measurement charts should be used, as using older ones may lead to an overestimation of the FL²⁴.

Caliper placement. Each caliper is placed at the ends of the ossified diaphysis without including the distal femoral epiphysis if it is visible (Figure 1c). This measurement should exclude triangular spur artifacts that can extend the diaphysis length falsely.

Estimated fetal weight (EFW)

Recommendations

- The Hadlock-3 formula (HC, AC, FL) appears to be the most stable mathematically, and its use is recommended in most clinical scenarios (**GRADE OF RECOMMENDATION: C**).
- The deviation of the estimated fetal size from the expected mean for the gestational age should be expressed as centile (or Z-score), and the chosen reference standard should be indicated in the report (**GOOD PRACTICE POINT**).
- Fetal biometry charts which are prescriptive, obtained prospectively, truly population-based and derived from studies with the lowest possible methodological bias should be favored (**GOOD PRACTICE POINT**).
- The use of the Delphi 2016 criteria should be used for the definition of fetal growth restriction (FGR) (**GOOD PRACTICE POINT**).

Mid-trimester sonographic measurements can be used to identify anomalies of fetal size²⁵. Estimated fetal weight (EFW) or AC can be used as a baseline parameter for the detection of subsequent growth problems²⁶.

Despite many efforts to develop new models for calculating EFW, the three-parameters (HC, AC, FL) formula reported by Hadlock *et al.*²⁵ provided the best fetal weight estimates in a large study cohort²⁷, and should be considered the method of choice for assessment of all fetuses, including those suspected to be either small or large¹³. Various approaches may be used to optimize the detection of abnormal growth¹⁴. However, the degree of deviation from normal at this early stage of pregnancy that would justify action (e.g. follow-up scan to assess fetal growth or fetal chromosomal analysis) has not been established. Recent research suggests that EFW as early as the mid trimester could be used in a competing-risks model to predict subsequent small-for-gestational age²⁸.

Additional measurements to demonstrate evidence of growth, taken at least 3 weeks from those obtained at a preceding scan, are usually reported as deviations from mean values with their expected ranges for a given age²⁹. This information should preferentially be expressed as percentile of a reference range or Z-score, or on a graph. The use of Z-scores allows monitoring of severe anomalies and facilitates data quality control. The chosen reference standards should be indicated in the report^{30,31}. Fetal biometry charts which are prescriptive, obtained prospectively, truly population-based and derived from studies with the lowest possible methodological bias should be favored, although practitioners should be aware of nationally or locally recommended charts¹³.

Whenever abnormal growth is suspected, the use of diagnostic criteria for fetal growth restriction (FGR) based on the Delphi 2016 consensus criteria should be encouraged^{13,14,32,33}. Abnormal umbilical artery Doppler indices and/or maternal symptoms of hypertension or pre-eclampsia should prompt emergency referral.

Amniotic fluid volume assessment

Recommendation

- Amniotic fluid index (AFI) may be preferable in assessing polyhydramnios, while deepest vertical pocket (DVP) may be preferable in assessing oligohydramnios (**GRADE OF RECOMMENDATION: C**).

The amount of amniotic fluid should be evaluated either subjectively, defined as 'normal' or 'abnormal' (reduced or increased), or semiquantitatively, by measurement of the deepest vertical pocket (DVP) of amniotic fluid or the amniotic fluid index (AFI). For DVP, the largest vertical pocket free of umbilical cord or fetal parts is measured. $DVP \leq 2.0$ cm is considered as decreased amniotic fluid volume, $DVP > 2$ cm and ≤ 8.0 cm as normal amniotic fluid volume, and $DVP > 8$ cm as increased amniotic fluid volume³⁴. Reference values for gestational age can also be used³⁵.

The AFI can be estimated from 18 weeks of gestation by measuring four vertical pockets free of umbilical cord and/or fetal parts, one from each quadrant of the uterus³⁶. Both AFI and DVP correlate poorly with the actual dye-calculated volume of amniotic fluid, and neither of them appears significantly better than the other³⁷. However, it appears that AFI identifies more women as having oligohydramnios than does DVP, thereby increasing the rate of labor induction, but without improving the clinical outcome^{37,38}. Observational evidence comparing ultrasound with dye-determination of amniotic fluid volume has shown that DVP may be superior for identifying oligohydramnios and the AFI superior for identifying polyhydramnios³⁹. Recommendations for performing semiquantitative assessment of the amniotic fluid volume are:

- (i) hold the ultrasound transducer perpendicular to the maternal position;
- (ii) identify clear boundaries of the upper and lower edges of the pocket;
- (iii) measure the largest unobstructed amniotic fluid pocket;
- (iv) use color Doppler for areas where the umbilical cord is not visualized clearly.

Amniotic membranes

From 16 weeks onwards, the amnion and chorion are usually fused. Amniotic sheets are benign findings, to be distinguished from amniotic bands which may cause fetal deformities^{40–42}.

Fetal movement

Normal fetuses typically have a neutral position and show regular movements. Temporary absence of or a reduction in fetal movements during the scan should not be considered as a risk factor⁴³. Abnormal positioning or unusually restricted or persistently absent fetal movements may suggest abnormal fetal conditions, such as arthrogryposis, and should prompt a request for referral⁴⁴. The biophysical profile is not considered part of the routine mid-trimester scan⁴⁵.

Umbilical cord

Recommendations

- Although formal assessment of the umbilical cord insertion is not part of the routine mid-trimester scan, if marginal or velamentous cord insertion is visualized, it should be reported (**GOOD PRACTICE POINT**).
- When a single umbilical artery is identified in the mid-trimester scan, care should be taken not to cause anxiety to the parents if there is no evidence of coexisting structural defects or FGR (**GOOD PRACTICE POINT**).

The insertion of the umbilical cord is in the center of the placenta in about 80% of cases, paracentral in about 12% of cases and marginal (within 2 cm of the placental edge) in 5–8% of cases. Velamentous insertion occurs in approximately 1% of cases, and is defined as insertion of the umbilical vessels within the amniotic membranes instead of the placenta⁴⁶. A velamentous cord insertion may be associated with vasa previa and FGR. When marginal or velamentous insertion is visualized, it should be reported; however, formal assessment of umbilical cord insertion on the placenta is not part of the routine mid-trimester scan⁴⁷.

Number of vessels. Single umbilical artery (SUA) is the result of obliteration or atrophy of one of the arteries, most commonly the left⁴⁸. It is more frequent in twin pregnancy. The diagnosis is made by direct visualization of the umbilical cord, or by tracking the umbilical arteries around the fetal bladder with color Doppler. SUA is associated with congenital anomalies and FGR⁴⁹, although it does not constitute an anomaly *per se*. Therefore, care should be taken not to cause anxiety to the parents if no major anomaly is found at the mid-trimester scan. There is, as yet, no consensus regarding the potential impact of SUA on pregnancy outcome^{50,51}.

Coiling. Coiling describes the spiral course of the umbilical arteries in the cord. Increased or reduced umbilical cord coiling have no proven significance and should not be reported as part of the routine mid-trimester scan⁵².

Doppler ultrasonography

Recommendation

- There is currently insufficient evidence to support universal use of uterine or umbilical artery pulsed Doppler evaluation for the screening of low-risk pregnant women (**GRADE OF RECOMMENDATION: C**).

The application of pulsed-wave Doppler techniques is not currently recommended as part of the routine mid-trimester ultrasound examination. There is insufficient evidence to support universal use of uterine or umbilical artery pulsed Doppler evaluation for the screening of low-risk pregnancies⁵³. Color-flow Doppler imaging is encouraged and can assist in the examination of the fetal heart and the cord vessels and in determination of the amount of amniotic fluid.

Multiple gestation

Recommendations

- Chorionicity should be determined in the first trimester, if possible (**GRADE OF RECOMMENDATION: C**).
- When no first-trimester ultrasound examination has been performed and it is not possible to identify two

separate placentae and the fetal gender is the same, the pregnancy should be considered as monochorionic (GOOD PRACTICE POINT).

The evaluation of multiple pregnancy should follow specific guidelines⁵⁴ and includes the following additional elements:

- determination of chorionicity (and, in monochorionic placentation, amnionicity) may be feasible in the mid trimester, for example, if there are clearly two separate placental masses or the fetal gender is discordant (although there are exceptions to these rules); however, chorionicity is better evaluated before 14–15 weeks, when the lambda sign or T-sign can be determined;
- visualization of the placental cord insertion;
- reporting of distinguishing features (gender, unique markers, position in uterus), as it is critical to label twins correctly⁵⁵.

When no first-trimester ultrasound examination has been performed and it is not possible to identify two separate placentae and the fetal gender is the same, the pregnancy should be considered as monochorionic and referred or followed as a high-risk pregnancy. Local guidelines and clinical practice should be followed.

Anatomical survey

Suggested minimum requirements for a basic fetal anatomical survey during the mid trimester of pregnancy are summarized in Table 1. If any anomaly is suspected, then a more detailed examination or referral to an expert center should be considered.

Head

Recommendations

- The basic examination of the skull should include assessment of its size, shape, integrity and bone density (GOOD PRACTICE POINT).
- The basic examination of the brain should include two axial planes (transventricular and transthalamic) for assessment of the hemispheres, and an additional axial transcerebellar plane for assessment of the posterior fossa (GOOD PRACTICE POINT).

Skull. Four aspects of the fetal skull should be evaluated routinely: size, shape, integrity and bone density. All these characteristics can be visualized at the time of the head measurements, when the brain is evaluated for anatomical integrity also (Figure 2)⁵⁶.

- Size: measurements are performed as explained in the biometry section.
- Shape: the skull normally has an oval shape without focal protrusions or defects and is interrupted only by

Table 1 Suggested minimum (and *optional) requirements for basic mid-trimester fetal anatomical survey

Head	Intact cranium Head shape normal Cavum septi pellucidi normal in appearance Choroid plexus normal in appearance Midline falx normal in appearance Thalami normal in appearance Lateral cerebral ventricles normal in appearance Cerebellum normal in appearance Cisterna magna normal in appearance Nuchal fold* normal in appearance
Face	Both orbits and bulbi present Midsagittal facial profile* normal in appearance Nasal bone* normal in appearance Upper lip intact
Neck	Absence of masses (e.g. cystic hygroma)
Chest/heart	Chest and lungs appearing normal in shape/size Heart activity present Four-chamber view of heart in normal position (left chambers on left side) Aortic and pulmonary outflow tracts (relative size and their relationships) normal LVOT view; three-vessel view or three-vessels-and-trachea view normal No evidence of diaphragmatic hernia
Abdomen	Stomach in normal position on left side Bowel normal (not dilated or hyperechogenic) Gallbladder on right side* Both kidneys present, no pyelectasis Urinary bladder normal in appearance Cord insertion site into the fetal abdomen normal
Skeletal	No spinal defects or masses (transverse and sagittal views) Arms and hands present, normal joint position Legs and feet present, normal joint position
Placenta	Placental position and relation to cervix normal No masses present
Umbilical cord	Three-vessel cord* Cord insertion into placenta* normal
Genitalia	Normal male or female genitalia*
Cervix	Cervical-length measurement normal*

*Optional component of checklist: can be evaluated if technically feasible and according to local practice. LVOT, left ventricular outflow tract.

narrow, echolucent sutures. Alterations of shape (e.g. lemon, strawberry, cloverleaf) should be documented and investigated^{57,58}.

- Integrity: no bony defects should be present. Rarely, brain tissue can extrude through defects, for example, of the frontal or occipital bones.
- Bone density: normally, high skull density manifests as a continuous echogenic structure that is interrupted only by cranial sutures in specific anatomical locations. The absence of this whiteness or unusually clear visualization of the fetal brain should raise suspicion




Figure 2 Transverse views of the fetal head, demonstrating standard transventricular (a), transcerebellar (b) and transthalamic (c) scanning planes. The transventricular and transthalamic planes allow assessment of the anatomical integrity of the cerebral hemisphere regions. The transcerebellar plane permits evaluation of the cerebellum and cisterna magna (CM) in the posterior fossa. CP, choroid plexus; CSP, cavum septi pellucidi; Th, thalamus.

of poor mineralization (e.g. osteogenesis imperfecta, hypophosphatasia)⁵⁹.

Brain. Standard scanning planes for the basic examination of the fetal brain are described in the updated ISUOG Guidelines²⁰. Two axial planes, commonly referred to as the transventricular and transthalamic planes, permit visualization of the cerebral structures relevant to the anatomical integrity of the brain (Figure 2). Imaging artifacts obscure the proximal hemisphere (the one closer to the transducer). A third axial, transcerebellar, plane should be added to evaluate the posterior fossa. The following brain structures should be evaluated:

- lateral ventricles (including choroid plexus);
- cavum septi pellucidi;
- midline falx;
- thalami;
- cerebellum;
- cisterna magna.

Face

Recommendation

- The basic examination of the face should include visualization of the upper lip, assessment of the presence and position of the orbits/eyes, and, if possible, assessment of the fetal profile (**GOOD PRACTICE POINT**).

Evaluation of the fetal face should include visualization of the upper lip in the coronal (frontal) view to detect cleft lip⁶⁰ (Figure 3a) and, if feasible, the midsagittal facial profile (Figure 3b). The presence of both orbits and normal position and separation of the eyes should be checked (Figure 3c). Other anatomical landmarks, such as nose, nostrils, palate, maxilla, mandible, tongue^{61–63} and ear position and size, may be assessed, but are not part of the routine mid-trimester examination⁶⁴. Three-dimensional ultrasound may be a useful tool for




Figure 3 Ultrasound imaging of the fetal face. (a) The mouth, lips and nose are typically evaluated in a coronal view. (b) If technically feasible, a midsagittal facial profile should be obtained, as it provides important diagnostic clues for bilateral cleft lip, frontal bossing, micrognathia and nasal-bone anomalies. (Note that examination of the nasal bone is optional.) (c) Both fetal orbits should appear symmetrical and intact, with eyes separated by approximately the diameter of one orbit.

examination of the fetal face⁶⁵, although this is not part of the routine evaluation.

Neck

Recommendation

- The presence of obvious neck masses should be documented (**GOOD PRACTICE POINT**).

The neck normally appears as cylindrical, with no protuberances, masses or fluid collections. Obvious neck masses, such as cystic hygromas, goiter or teratomas, should be documented⁶⁶.

Thorax

Recommendation

- The basic examination of the thorax should include assessment of its shape and transition to the abdomen, the shape of the ribs, the texture of the lungs and, when feasible, visualization of the diaphragm (**GOOD PRACTICE POINT**).

The shape of the thorax should be regular, with a smooth transition to the abdomen⁶⁷. The ribs should have normal curvature, without deformity. Both lungs should appear homogeneous and without evidence of mediastinal shift or masses⁶⁸. The diaphragmatic interface can often be visualized as a hypoechoic dividing line between the thoracic and abdominal content (e.g. between heart and stomach or lung and liver)^{69,70}.

Heart

Recommendations

- The examination of the heart should start with assessment of its situs, axis and rhythm (**GOOD PRACTICE POINT**).
- The anatomical examination of the heart should include the four-chamber view, the outflow tract views and the three-vessel view (**GOOD PRACTICE POINT**).

Fetal cardiac screening is performed for the detection of congenital heart disease during the mid-trimester scan (Figure 4)⁷¹. A single acoustic focal zone and relatively narrow field of view can help to maximize frame rates. Images should be magnified until the heart fills at least one-third to one-half of the ultrasound display screen.

The scanning procedure should begin with a four-chamber view of the fetal heart. A normal, regular heart rate typically ranges from 120 to 160 bpm. The heart is positioned in the left chest (as is the fetal stomach) if the *situs* is normal. A normal heart is usually no larger than one-third of the area of the chest and is without pericardial effusion. The heart axis deviates by approximately $45 \pm 20^\circ$ (2 SD) towards the left side of the fetus⁷². Routine cardiac screening should also assess the aortic and pulmonary outflow tracts to detect cardiac malformations beyond those achievable using the four-chamber view alone (Figure 4a). Normal-appearing great vessels are approximately equal in size and should cross each other as they exit their respective ventricular chambers (Figure 4b,c). Routine assessment of the cardiac outflow tracts in addition to the four-chamber view increases the screening performance for identifying conotruncal anomalies, such as tetralogy of Fallot, transposition of the great arteries, double-outlet right ventricle and truncus arteriosus communis. The three-vessel view and closely related three-vessels-and-trachea view may improve detection of outflow tract, aortic arch and systemic vein anomalies (Figure 4d,e)^{73–77}. For a more detailed description of fetal cardiac screening, please refer to the ISUOG Guidelines for the fetal cardiac examination⁷¹.

Abdomen

Recommendations

- The presence, situs and shape of the stomach should be examined (**GOOD PRACTICE POINT**).




Figure 4 Representative scan planes for mid-trimester fetal cardiac screening. Determination of cardiac *situs* with the fetal stomach and the fetal heart in the same left-sided position (not shown). The four-chamber view (4CV) (a) includes two atria, left and right (LA and RA), and two ventricles, left and right (LV and RV), with offset atrioventricular valves and intact ventricular septum. The left ventricular outflow tract (b) (arrow) and right ventricular outflow tract (c) (arrow) are imaged routinely. Both arterial outflow tracts are approximately equal in size and exit their respective ventricles by crossing over each other in normal fetuses. The three-vessel view (d) (pulmonary artery (Pa), ascending aorta (Ao) and right superior vena cava (SVC)) and three-vessels-and-trachea view (e) (ductal arch (Da), aortic arch (AA), right superior vena cava (SVC) and trachea (Tr)) are documented in addition to the 4CV.

- From left to right, the stomach, umbilical vein and gallbladder should be visualized. Assessment of the gallbladder is optional (**GOOD PRACTICE POINT**).
- The fetal umbilical cord insertion site should be examined (**GOOD PRACTICE POINT**).
- Abnormal fluid collections in or around the bowel should be documented (**GOOD PRACTICE POINT**).
- Increased echogenicity of the bowel, equal to that of bone, should prompt referral (**GOOD PRACTICE POINT**).

Abdominal-organ *situs* should be determined⁷⁸. The fetal stomach should be clearly visible in its normal position on the left side and should occupy about one-third of the left half of the transverse section of the fetal abdomen used for AC measurement. Any abnormality in the position/location of the stomach or any significant deviation in size (persistent non-visualization or barely visible stomach, stomach expanding beyond the midline or presence of the ‘double bubble’) should prompt referral. Three hypoechoic structures should be identified in the upper fetal abdomen: from left to right, the stomach, umbilical vein and gallbladder (assessment of the gallbladder is optional). An abnormal location of

any of these structures may be associated with a congenital anomaly (e.g. persistent right umbilical vein, heterotaxy, portohepatic shunt). The bowel should be contained within the abdomen. The fetal umbilical cord insertion site (Figure 5a) should be examined for evidence of a ventral wall defect, such as omphalocele or gastroschisis. Abnormal fluid collections in or around the bowel (e.g. ascites, enteric cysts, obvious bowel dilatation) should be documented. Increased echogenicity of the bowel, equal to that of bone, should also be a reason for referral; in order to avoid false positives, ultrasound grayscale gain should be decreased to check whether, under these circumstances, the suspected bowel remains more echoic than adjacent bones, such as the iliac crest⁷⁹.

Kidneys and bladder

Recommendations

- The fetal bladder and both kidneys should be visualized (**GOOD PRACTICE POINT**).
- If either bladder or renal pelvis appears enlarged, a detailed assessment should follow (**GOOD PRACTICE POINT**).




Figure 5 Ultrasound imaging of the fetal cord insertion site and bladder, with umbilical arteries, kidneys and spine. The umbilical cord insertion site into the fetal abdomen (a, arrow) provides information about the presence of ventral wall defects, such as omphalocele or gastroschisis. The fetal bladder (b, ☆) and both kidneys (c, arrows) should be identified. Axial and longitudinal views of the spine (c,d) including a clearly visible intact skin line provide effective screening for spina bifida, especially when these scanning planes are abnormal in the presence of frontal skull deformation and an obliterated cisterna magna.

The fetal bladder and both kidneys should be visualized (Figure 5b,c). If either the bladder or renal pelvis appears enlarged, a measurement should be documented. A renal pelvis ≥ 7 mm indicates a need for reassessment in the third trimester^{80,81}. The fetal bladder should not reach the level of the umbilical cord insertion. At 18 and 22 weeks, the 95th centile for the longitudinal bladder measurement is 14 and 23 mm, respectively⁸². An abnormally enlarged fetal bladder or persistent failure to visualize the bladder should prompt referral for a more detailed assessment.

Spine

Recommendation

- The basic examination of the fetal spine should include transverse and sagittal views (GOOD PRACTICE POINT).

A satisfactory examination of the fetal spine requires expertise and meticulous scanning, and the results are very dependent upon fetal position. Complete evaluation of the fetal spine in every plane is not part of the basic examination, although transverse (Figure 5c) and sagittal (Figure 5d) views are usually informative. The most frequent severe spinal anomaly, open spina bifida, is usually associated with a characteristic cerebellar deformity and an obliterated cisterna magna⁸³. Other views of the fetal spine may identify other spinal malformations, including vertebral anomalies and sacral agenesis²⁰.

Limbs and extremities

Recommendations

- The presence of all four extremities should be documented (GOOD PRACTICE POINT).




Figure 6 Sonography of the fetal upper (a) and lower (b) extremities. The presence or absence of the upper and lower limbs should be documented routinely unless they are poorly visualized due to technical factors.

- The presence of all long bones and their symmetry, length, shape, alignment, position and movement should be assessed (**GOOD PRACTICE POINT**).
- Counting fingers or toes is not required as part of the routine mid-trimester scan (**GOOD PRACTICE POINT**).
- The measurement of one femur is usually sufficient, unless there is suspicion of abnormality (**GOOD PRACTICE POINT**).

The presence or absence of both arms and hands (Figure 6a) and both legs and feet (Figure 6b) should be documented using a systematic approach⁸⁴. All four limbs should be surveyed, noting presence of all long bones and their symmetry, length, shape, alignment, position and movement. Counting fingers or toes is not required as part of the routine mid-trimester scan. Usually, measurement of one femur is sufficient, but if there is concern, then all long bones should be measured and measurements compared with standardized charts⁸⁵. Suspected deviations from normal at the standard examination should prompt a more detailed examination⁸⁶ and expert evaluation and counseling for possible skeletal dysplasia and genetic and non-genetic syndromes.

Genitalia

Recommendation

- Although examination of the fetal genitalia for sex determination is not part of the routine mid-trimester scan, their normal appearance should be checked (**GOOD PRACTICE POINT**).

Characterization of external genitalia to determine fetal gender is not considered part of the routine mid-trimester scan. Reporting of gender should be considered only on parental request and in the context of local practice and regulations. However, the normal appearance of the external genitalia should be checked.

Placenta

Recommendations

- The relationship of the placenta with the internal cervical os should be examined (**GOOD PRACTICE POINT**).




Figure 7 Placental position should be determined in relation to the maternal cervix (dashed arrow).

- If the distance between the lower placental edge and the internal os is ≤ 15 mm on transvaginal scan, a follow-up examination in the third trimester is recommended (**GRADE OF RECOMMENDATION: C**).
- If placenta accreta is suspected at the routine mid-trimester scan, a more detailed evaluation is suggested (**GOOD PRACTICE POINT**).

The placental location (Figure 7), its relationship with the internal cervical os (usually using transabdominal insonation) and its appearance should be assessed and described. Examples of abnormal placental findings include the presence of hemorrhage, multiple anechoic cysts (distinct from normal lacunae) in triploidy, and placental masses, such as chorioangioma. In most cases, in the routine mid-trimester examination, transabdominal ultrasonography permits clear definition of the relationship between the placenta and the internal cervical os. If the lower placental edge reaches or overlaps the internal os, a follow-up examination in the third trimester is recommended^{87–89}. Although there is little evidence for the optimal cut-off for reassessment of a low-lying placenta⁹⁰, recently suggested cut-offs for likely placental migration for an anteriorly and a posteriorly located placenta were 5 mm and 15.5 mm, respectively, from the internal os, using transvaginal imaging at the mid-trimester scan⁹¹. ‘Migration’ of low-positioned

placentae (i.e. growth of the uterine wall between the placental edge and the internal os) during pregnancy is frequent, and follow-up in the third trimester will confirm normal placental position in most cases⁹². Women with a history of uterine surgery and low anterior placenta or placenta previa are at risk for placenta accreta spectrum disorders. In these cases, the placenta should be examined for findings such as: lack of the hypoechoic myometrial line below the placenta; large and irregular placental lacunae; interruption of the hyperechoic line between the uterine serosa and the bladder; reduced thickness (< 1 mm) of the myometrium underlying the placenta; and placental bulge^{93,94}. Although placenta accreta may be suspected during a routine mid-trimester scan, a more detailed evaluation is usually required to examine this possibility further^{87,93}.

Screening for vasa previa

Recommendation

- In the presence of risk factors for vasa previa, a targeted examination using a transvaginal approach is recommended, depending on experience and resources (**GRADE OF RECOMMENDATION: B**).

Vasa previa, defined as unprotected fetal vessels running through the fetal membranes, over or within 2 cm of the internal cervical os, is found in approximately 0.5 per 1000 pregnancies in the general population. Risk factors for vasa previa include twin pregnancy, conception by assisted reproductive technology, a low-lying or bilobed placenta, succenturiate placental lobes and velamentous cord insertion⁹⁵. If such risk factors are identified, a targeted examination is suggested, given that prenatal knowledge of vasa previa significantly increases survival and decreases perinatal morbidity⁹⁶. This can be done using a transvaginal approach with color Doppler imaging^{88,97,98}. Similarly, when the transabdominal scan suggests the possibility of placenta previa or shortened/dilated maternal cervix, using transvaginal sonography with color Doppler imaging may also be of benefit. There is, however, ongoing debate regarding whether routine screening for velamentous cord insertion and/or vasa previa should be performed at the mid-trimester scan; the evidence is of limited quality and fails to take into account the consequences of over-diagnosing such anomalies^{47,88}. Furthermore, not all medical practices may have sufficient experience in transvaginal sonography or the resources for proper disinfection procedures.

Cervix, uterus and adnexa

Recommendations

- When feasible, transvaginal CL measurement should be performed at the mid-trimester scan in the

context of screening for preterm birth (**GRADE OF RECOMMENDATION: C**).

- This assessment requires additional consent from the woman, appropriate operator training and auditing of the results (**GOOD PRACTICE POINT**).

Several studies have demonstrated a strong correlation between short transvaginal sonographic CL, usually defined as <25 mm, especially before 24 weeks, and subsequent preterm birth. CL measurements can be performed as part of the routine mid-trimester scan, by transvaginal imaging, which requires separate consent from the woman, appropriate operator training³ and auditing of the results. Meta-analyses of randomized controlled trials of women with singleton gestation, no prior spontaneous preterm birth and transvaginal sonographic CL < 25 mm before 24 weeks have shown that administration of vaginal progesterone significantly decreases the risk of preterm birth and neonatal morbidity^{99–101}. Two cost-effectiveness analyses have shown that measurement of CL in the mid trimester and progesterone supplementation in women with a short cervix appears to be a cost-effective screening strategy for preterm birth^{102,103}. For these reasons, transvaginal ultrasound CL measurement is commonly recommended in the general population^{104–106}.

In women with singleton gestation, a short cervix and prior spontaneous preterm birth, cerclage is associated with significant decrease in the risk of preterm birth and neonatal morbidity and mortality¹⁰⁷. Several medical societies recommend serial transvaginal sonographic CL measurement at 16–23 weeks in this population^{104,105,108,109}.

The 'ISUOG Practice Guidelines: role of ultrasound in the prediction of spontaneous preterm birth' (in prep.) will provide more guidance and details.

GUIDELINE AUTHORS

L. J. Salomon, Department of Obstetrics and Fetal Medicine, Hôpital Necker-Enfants Malades, Assistance Publique-Hopitaux de Paris, Paris Cité University, Paris, France

Z. Alfirevic, Department of Women's and Children's Health, University of Liverpool, Liverpool, UK

V. Berghella, Thomas Jefferson University, Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Philadelphia, PA, USA

C. M. Bilardo, University Medical Centre, Fetal Medicine Unit, Department of Obstetrics & Gynecology, Groningen, The Netherlands

G. E. Chalouhi, Maternité Necker-Enfants Malades, Université Paris Descartes, AP-HP, Paris, France

F. Da Silva Costa, Maternal Fetal Medicine Unit, Gold Coast University Hospital and School of Medicine, Griffith University, Gold Coast, Queensland, Australia

E. Hernandez-Andrade, University of Texas Health Science Center at Houston, Houston, TX, USA

G. Malinger, Division of Ob-Gyn Ultrasound, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center

and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

H. Munoz, University of Chile Hospital, Fetal Medicine Unit, Obstetrics & Gynecology, Santiago, Chile

D. Paladini, Fetal Medicine and Surgery Unit, Istituto G. Gaslini, Genoa, Italy

F. Prefumo, Division of Obstetrics and Gynaecology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

A. Sotiriadis, Second Department of Obstetrics and Gynecology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

A. Toi, Medical Imaging, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada

W. Lee, Baylor College of Medicine, Department of Obstetrics and Gynecology, Houston, TX, USA

ACKNOWLEDGMENTS

These guidelines were developed by the Prenatal Ultrasound Screening Task Force under the auspices of the ISUOG Clinical Standards Committee. Appreciation is extended, in particular, to specialty consultants who contributed to this project, notably Jacques Abramowicz (USA) for his contribution to the Safety section, and Jean-Philippe Bault (France) for providing some of the images.

CITATION

These Guidelines should be cited as: ‘Salomon LJ, Alfrevic Z, Berghella V, Bilardo CM, Chalouhi GE, Da Silva Costa F, Hernandez-Andrade E, Malinger G, Munoz H, Paladini D, Prefumo F, Sotiriadis A, Toi A, Lee W, on behalf of the ISUOG Clinical Standards Committee. ISUOG Practice Guidelines (updated): performance of the routine mid-trimester fetal ultrasound scan. *Ultrasound Obstet Gynecol* 2022. DOI: 10.1002/uog.24888.

REFERENCES

- Edwards L, Hui L. First and second trimester screening for fetal structural anomalies. *Semin Fetal Neonatal Med* 2018; 23: 102–111.
- Salomon LJ, Alfrevic Z, Berghella V, Bilardo C, Hernandez-Andrade E, Johnsen SL, Kalache K, Leung K-Y, Malinger G, Munoz H, Prefumo F, Toi A, Lee W, on behalf of the ISUOG Clinical Standards Committee. Practice guidelines for performance of the routine mid-trimester fetal ultrasound scan. *Ultrasound Obstet Gynecol* 2011; 37: 116–126.
- Kagan KO, Sonek J. How to measure cervical length. *Ultrasound Obstet Gynecol* 2015; 45: 358–362.
- ISUOG Practice Guidelines: performance of first-trimester fetal ultrasound scan. *Ultrasound Obstet Gynecol* 2013; 41: 102–113.
- Ritchie K, Bradbury I, Slattery J, Wright D, Iqbal K, Penney G. Economic modelling of antenatal screening and ultrasound scanning programmes for identification of fetal abnormalities. *BJOG* 2005; 112: 866–874.
- Lytzen R, Vejstrup N, Bjerre J, Petersen OB, Leenskjold S, Dodd JK, Jørgensen FS, Søndergaard L. Live-Born Major Congenital Heart Disease in Denmark: Incidence, Detection Rate, and Termination of Pregnancy Rate From 1996 to 2013. *JAMA Cardiol* 2018; 3: 829–837.
- ISUOG Education Committee recommendations for basic training in obstetric and gynecological ultrasound. *Ultrasound Obstet Gynecol* 2014; 43: 113–116.
- Tolsgaard MG, Chalouhi GE. Use of ultrasound simulators for assessment of trainee competence: trendy toys or valuable instruments? *Ultrasound Obstet Gynecol* 2018; 52: 424–426.
- The British Medical Ultrasound Society. Guidelines for the safe use of diagnostic ultrasound equipment. In *Diagnostic Ultrasound* (2nd edn), Hoskins PR, Martin K, Thrush A (eds). Cambridge University Press: Cambridge, 2010; 217–225.
- Salvesen K, Abramowicz J, Ter Haar G, Miloro P, Sinkovskaya E, Dall'Asta A, Maršál K, Lees C, on behalf of the Board of the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG). ISUOG statement on the non-diagnostic use of ultrasound in pregnancy. *Ultrasound Obstet Gynecol* 2021; 58: 147.
- Silvestri MT, Pettker CM, Raney JH, Xu X, Ross JS. Frequency and Importance of Incomplete Screening Fetal Anatomic Sonography in Pregnancy. *J Ultrasound Med* 2016; 35: 2665–2673.
- Waller SA, O'Connell K, Carter A, Gravett MG, Dighe M, Richardson ML, Dubinsky TJ. Incidence of fetal anomalies after incomplete anatomic surveys between 16 and 22 weeks. *Ultrasound Q* 2013; 29: 307–312.
- Salomon LJ, Alfrevic Z, Da Silva Costa F, Deter RL, Figueras F, Ghi T, Glanc P, Khalil A, Lee W, Napolitano R, Papageorgiou A, Sotiriadis A, Stirnemann J, Toi A, Yeo G. ISUOG Practice Guidelines: ultrasound assessment of fetal biometry and growth. *Ultrasound Obstet Gynecol* 2019; 53: 715–723.
- Lees CC, Stampalija T, Baschat A, da Silva Costa F, Ferrazzi E, Figueras F, Hecher K, Kingdom J, Poon LC, Salomon LJ, Unterscheider J. ISUOG Practice Guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. *Ultrasound Obstet Gynecol* 2020; 56: 298–312.
- Sarris I, Ioannou C, Dighe M, Mitidieri A, Oberto M, Qingqing W, Shah J, Sohoni S, Al Zidjali W, Hoch L, Altman DG, Papageorgiou AT, for the International Fetal and Newborn Growth Consortium for the 21st Century (INTERGROWTH-21st). Standardization of fetal ultrasound biometry measurements: improving the quality and consistency of measurements. *Ultrasound Obstet Gynecol* 2011; 38: 681–687.
- Cavallaro A, Ash ST, Napolitano R, Wanyonyi S, Ohuma EO, Molloholli M, Sande J, Sarris I, Ioannou C, Norris T, Donadono V, Carvalho M, Purwar M, Barros FC, Jaffer YA, Bertino E, Pang R, Gravett MG, Salomon LJ, Noble JA, Altman DG, Papageorgiou AT. Quality control of ultrasound for fetal biometry: results from the INTERGROWTH-21st Project. *Ultrasound Obstet Gynecol* 2018; 52: 332–339.
- Salomon LJ, Bernard JP, Duyme M, Doris B, Mas N, Ville Y. Feasibility and reproducibility of an image-scoring method for quality control of fetal biometry in the second trimester. *Ultrasound Obstet Gynecol* 2006; 27: 34–40.
- Sarris I, Ioannou C, Ohuma EO, Altman DG, Hoch L, Cosgrove C, Fathima S, Salomon LJ, Papageorgiou AT, International Fetal and Newborn Growth Consortium for the 21st Century. Standardisation and quality control of ultrasound measurements taken in the INTERGROWTH-21st Project. *BJOG* 2013; 120 (Suppl 2): 33–37.
- Papageorgiou AT, Kemp B, Stones W, Ohuma EO, Kennedy SH, Purwar M, Salomon LJ, Altman DG, Noble JA, Bertino E, Gravett MG, Pang R, Cheikh Ismail L, Barros FC, Lambert A, Jaffer YA, Victora CG, Bhutta ZA, Villar J, for the International Fetal and Newborn Growth Consortium for the 21st Century (INTERGROWTH-21st). Ultrasound-based gestational-age estimation in late pregnancy. *Ultrasound Obstet Gynecol* 2016; 48: 719–726.
- Malinger G, Paladini D, Haratz KK, Monteagudo A, Pilu GL, Timor-Tritsch IE. ISUOG Practice Guidelines (updated): sonographic examination of the fetal central nervous system. Part 1: performance of screening examination and indications for targeted neurosonography. *Ultrasound Obstet Gynecol* 2020; 56: 476–484.
- Hadlock FP, Deter RL, Carpenter RJ, Park SK. Estimating fetal age: effect of head shape on BPD. *AJR Am J Roentgenol* 1981; 137: 83–85.
- Napolitano R, Donadono V, Ohuma EO, Knight CL, Wanyonyi SZ, Kemp B, Norris T, Papageorgiou AT. Scientific basis for standardization of fetal head measurements by ultrasound: a reproducibility study. *Ultrasound Obstet Gynecol* 2016; 48: 80–85.
- Økland I, Bjåstad TG, Johansen TF, Gjessing HK, Grøttum P, Eik-Nes SH. Narrowed beam width in newer ultrasound machines shortens measurements in the lateral direction: fetal measurement charts may be obsolete. *Ultrasound Obstet Gynecol* 2011; 38: 82–87.
- Stirnemann JJ, Fries N, Bessis R, Fontanges M, Mangione R, Salomon LJ. Implementing the INTERGROWTH-21(st) fetal growth standards in France: a “flash study” of the Collège Français d’Échographie Foetale (CFEF). *Ultrasound Obstet Gynecol* 2017; 49: 487–492.
- Hadlock FP, Harrist RB, Sharman RS, Deter RL, Park SK. Estimation of fetal weight with the use of head, body, and femur measurements—a prospective study. *Am J Obstet Gynecol* 1985; 151: 333–337.
- McCowan LM, Figueras F, Anderson NH. Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. *Am J Obstet Gynecol* 2018; 218(2S): S855–S868.
- Hammami A, Mazer Zumaeta A, Syngelaki A, Akolekar R, Nicolaides KH. Ultrasonographic estimation of fetal weight: development of new model and assessment of performance of previous models. *Ultrasound Obstet Gynecol* 2018; 52: 35–43.
- Papastefanou I, Nowacka U, Syngelaki A, Dragoi V, Karamanis G, Wright D, Nicolaides KH. Competing-risks model for prediction of small-for-gestational-age neonate from estimated fetal weight at 19–24 weeks’ gestation. *Ultrasound Obstet Gynecol* 2021; 57: 917–924.
- Mongelli M, Ek S, Tambyrajia R. Screening for fetal growth restriction: a mathematical model of the effect of time interval and ultrasound error. *Obstet Gynecol* 1998; 92: 908–912.
- Salomon LJ, Bernard JP, Duyme M, Buvat I, Ville Y. The impact of choice of reference charts and equations on the assessment of fetal biometry: Assessment of fetal biometry. *Ultrasound Obstet Gynecol* 2005; 25: 559–565.

31. Ioannou C, Talbot K, Ohuma E, Sarris I, Villar J, Conde-Agudelo A, Papageorghiou A. Systematic review of methodology used in ultrasound studies aimed at creating charts of fetal size. *BJOG* 2012; **119**: 1425–1439.
32. Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, Silver RM, Wynia K, Ganzevoort W. Consensus definition of fetal growth restriction: a Delphi procedure. *Ultrasound Obstet Gynecol* 2016; **48**: 333–339.
33. Gordijn SJ, Beune IM, Ganzevoort W. Building consensus and standards in fetal growth restriction studies. *Best Pract Res Clin Obstet Gynaecol* 2018; **49**: 117–126.
34. Chamberlain PF, Manning FA, Morrison I, Harman CR, Lange IR. Ultrasound evaluation of amniotic fluid volume. I. The relationship of marginal and decreased amniotic fluid volumes to perinatal outcome. *Am J Obstet Gynecol* 1984; **150**: 245–249.
35. Peixoto AB, da Cunha Caldas TMR, Giannecchini CV, Rolo LC, Martins WP, Araujo Júnior E. Reference values for the single deepest vertical pocket to assess the amniotic fluid volume in the second and third trimesters of pregnancy. *J Perinat Med* 2016; **44**: 723–727.
36. Magann EF, Sanderson M, Martin JN, Chauhan S. The amniotic fluid index, single deepest pocket, and two-diameter pocket in normal human pregnancy. *Am J Obstet Gynecol* 2000; **182**: 1581–1588.
37. Magann EF, Chauhan SP, Doherty DA, Magann MI, Morrison JC. The evidence for abandoning the amniotic fluid index in favor of the single deepest pocket. *Am J Perinatol* 2007; **24**: 549–555.
38. Kehl S, Schelkle A, Thomas A, Puhl A, Meqdad K, Tuschy B, Berlit S, Weiss C, Bayer C, Heimrich J, Dammer U, Raabe E, Winkler M, Faschingbauer F, Beckmann MW, Sütterlin M. Single deepest vertical pocket or amniotic fluid index as evaluation test for predicting adverse pregnancy outcome (SAFE trial): a multicenter, open-label, randomized controlled trial. *Ultrasound Obstet Gynecol* 2016; **47**: 674–679.
39. Hughes DS, Magann EF, Whittington JR, Wendel MP, Sandlin AT, Ounpraseuth ST. Accuracy of the Ultrasound Estimate of the Amniotic Fluid Volume (Amniotic Fluid Index and Single Deepest Pocket) to Identify Actual Low, Normal, and High Amniotic Fluid Volumes as Determined by Quantile Regression. *J Ultrasound Med* 2020; **39**: 373–378.
40. Pleş L, Sima RM, Moisei C, Moga MA, Dracea L. Abnormal ultrasound appearance of the amniotic membranes - diagnostic and significance: a pictorial essay. *Med Ultrason* 2017; **19**: 211–215.
41. Shetty P, Menezes LT, Tauro LF, Diddigi KA. Amniotic band syndrome. *Indian J Surg* 2013; **75**: 401–402.
42. Society for Maternal-Fetal Medicine, Gandhi M, Rac MWF, McKinney J. Amniotic Band Sequence. *Am J Obstet Gynecol* 2019; **221**: B5–B6.
43. de Vries JI, Fong BF. Normal fetal motility: an overview. *Ultrasound Obstet Gynecol* 2006; **27**: 701–711.
44. Bonilla-Musoles F, Machado LE, Osborne NG. Multiple congenital contractures (congenital multiple arthrogryposis). *J Perinat Med* 2002; **30**: 99–104.
45. Manning FA. Fetal biophysical profile. *Obstet Gynecol Clin North Am* 1999; **26**: 557–577.
46. Padula F, Laganà AS, Vitale SG, Mangiafico L, D'Emidio L, Cignini P, Giorlandino M, Gulino FA, Capriglione S, Giorlandino C. Ultrasonographic evaluation of placental cord insertion at different gestational ages in low-risk singleton pregnancies: a predictive algorithm. *Facts Views Vis ObGyn* 2016; **8**: 3–7.
47. Buchanan-Hughes A, Bobrowska A, Visintin C, Attilakos G, Marshall J. Velamentous cord insertion: results from a rapid review of incidence, risk factors, adverse outcomes and screening. *Syst Rev* 2020; **9**: 147.
48. Santillan M, Santillan D, Fleener D, Stegmann B, Zamba G, Hunter S, Yankowitz J. Single umbilical artery: Does side matter? *Fetal Diagn Ther* 2012; **32**: 201–208.
49. Hasegawa J. Ultrasound screening of umbilical cord abnormalities and delivery management. *Placenta* 2018; **62**: 66–78.
50. Kim HJ, Kim JH, Chay DB, Park JH, Kim MA. Association of isolated single umbilical artery with perinatal outcomes: Systemic review and meta-analysis. *Obstet Gynecol Sci* 2017; **60**: 266–273.
51. Voskamp BJ, Fleurke-Rozema H, Oude-Rengerink K, Snijders RJM, Bilardo CM, Mol BWJ, Pajkrt E. Relationship of isolated single umbilical artery to fetal growth, aneuploidy and perinatal mortality: systematic review and meta-analysis. *Ultrasound Obstet Gynecol* 2013; **42**: 622–628.
52. Sebire NJ. Pathophysiological significance of abnormal umbilical cord coiling index. *Ultrasound Obstet Gynecol* 2007; **30**: 804–806.
53. Alfirevic Z, Stampalija T, Medley N. Fetal and umbilical Doppler ultrasound in normal pregnancy. *Cochrane Database Syst Rev* 2015; **(4)**: CD001450.
54. ISUOG Practice Guidelines: role of ultrasound in twin pregnancy. *Ultrasound Obstet Gynecol* 2016; **47**: 247–263.
55. Dias T, Arcangeli T, Bhide A, Napolitano R, Mahsud-Dornan S, Thilaganathan B. First-trimester ultrasound determination of chorionicity in twin pregnancy. *Ultrasound Obstet Gynecol* 2011; **38**: 530–532.
56. Aubry MC, Aubry JP, Dommergues M. Sonographic prenatal diagnosis of central nervous system abnormalities. *Childs Nerv Syst* 2003; **19**: 391–402.
57. Miller C, Losken HW, Towbin R, Bowen A, Mooney MP, Towbin A, Faix RS. Ultrasound diagnosis of craniosynostosis. *Cleft Palate Craniofac J* 2002; **39**: 73–80.
58. Delahaye S, Bernard JP, Renier D, Ville Y. Prenatal ultrasound diagnosis of fetal craniosynostosis. *Ultrasound Obstet Gynecol* 2003; **21**: 347–353.
59. Brown BS. The prenatal ultrasonographic diagnosis of osteogenesis imperfecta lethalis. *J Can Assoc Radiol* 1984; **35**: 63–66.
60. Rotten D, Levaillant JM. Two- and three-dimensional sonographic assessment of the fetal face. 1. A systematic analysis of the normal face. *Ultrasound Obstet Gynecol* 2004; **23**: 224–231.
61. Pilu G, Segata M. A novel technique for visualization of the normal and cleft fetal secondary palate: angled insonation and three-dimensional ultrasound. *Ultrasound Obstet Gynecol* 2007; **29**: 166–169.
62. Fuchs F, Grosjean F, Captier G, Faure JM. The 2D axial transverse views of the fetal face: A new technique to visualize the fetal hard palate; methodology description and feasibility. *Prenat Diagn* 2017; **37**: 1353–1359.
63. Frisova V, Cojocaru L, Turan S. A new two-dimensional sonographic approach to the assessment of the fetal hard and soft palates. *J Clin Ultrasound JCU* 2021; **49**: 8–11.
64. AIUM Practice Parameter for the Performance of Detailed Second- and Third-Trimester Diagnostic Obstetric Ultrasound Examinations. *J Ultrasound Med* 2019; **38**: 3093–3100.
65. Tutschek B, Blaas HGK, Abramowicz J, Baba K, Deng J, Lee W, Merz E, Platt L, Pretorius D, Timor-Tritsch IE, Gindes L, ISUOG 3D Special Interest Group. Three-dimensional ultrasound imaging of the fetal skull and face. *Ultrasound Obstet Gynecol* 2017; **50**: 7–16.
66. Zieliński R, Respondek-Liberska M. The role of prenatal ultrasound assessment in management of fetal cervicofacial tumors. *Arch Med Sci AMS* 2016; **12**: 850–855.
67. Azouz EM, Teebi AS, Eydoux P, Chen MF, Fassier F. Bone dysplasias: an introduction. *Can Assoc Radiol J* 1998; **49**: 105–109.
68. Delacourt C, Bertille N, Salomon LJ, Benachi A, Henry E, Massardier J, Mottet N, Rosenthal J, Sartor A, Thong-Vanh C, Valat-Rigot AS, Winer N, Lelong N, Khoshood B, for the Prenatal MALFPULM Study Group, Alanio E, Bory J -P, Aquilue LN, Choupeaux L, Hauw C, Banaszkiewicz N, Bertorello S, Lebouar G, Biquard F, Sentilhes L, Bonfiglioli V, Carbillon L, Bonnard A, Bremont F, Bultez T, Roth P, Stirnemann J, Ville Y, Castaigne V, Touboul C, Coatelevan F, Mangione R, Darras A -M., Guilbaud L, Jouannic J-M., Dazel-Salonne C, Ducoin H, Dugue-Marchaud M, Goua V, Eszto-Cambon M-L., Fange C, Prieur F, Favre R, Feghali H, Goffinet F, Tsatsaris V, Gondry J, Muszynski C, Hameury F, Laurichesse H, Lebras M -N., Letourneau A, Saada J, Morel O, Perdriolle E, Morin M, Mottet N, Mousty E, Oury J -F., Paris A, Perrotin F, Piolat C, Povedin G, Quibel T, Rakza T, Saliou A -H., Steir R, Thumerelle C, Trastour C. Prenatal natural history of congenital pulmonary malformations: MALFPULM population-based cohort study. *Ultrasound Obstet Gynecol* 2019; **54**: 381–388.
69. Ruano R, Benachi A, Aubry MC, Bernard JP, Hameury F, Nihoul-Fekete C, Dumez Y. Prenatal sonographic diagnosis of congenital hiatal hernia. *Prenat Diagn* 2004; **24**: 26–30.
70. Blaas HG, Eik-Nes SH. Sonographic development of the normal foetal thorax and abdomen across gestation. *Prenat Diagn* 2008; **28**: 568–580.
71. International Society of Ultrasound in Obstetrics and Gynecology, Carvalho JS, Allan LD, Chauoi R, Copel JA, DeVore GR, Hecher K, Lee W, Munoz H, Paladini D, Tutschek B, Yagel S. ISUOG Practice Guidelines (updated): sonographic screening examination of the fetal heart. *Ultrasound Obstet Gynecol* 2013; **41**: 348–359.
72. Comstock CH. Normal fetal heart axis and position. *Obstet Gynecol* 1987; **70**: 255–259.
73. Chauoi R, Heling KS, Lopez AS, Thiel G, Karl K. The thymic-thoracic ratio in fetal heart defects: a simple way to identify fetuses at high risk for microdeletion 22q11. *Ultrasound Obstet Gynecol* 2011; **37**: 397–403.
74. Karl K, Heling KS, Sarut Lopez A, Thiel G, Chauoi R. Thymic-thoracic ratio in fetuses with trisomy 21, 18 or 13. *Ultrasound Obstet Gynecol* 2012; **40**: 412–417.
75. Everwijn SMP, van Nesselrooij AEL, Rozendaal L, Clur SAB, Pajkrt E, Hruđa J, Linskens IH, van Lith JM, Blom NA, Haak MC. The effect of the introduction of the three-vessel view on the detection rate of transposition of the great arteries and tetralogy of Fallot. *Prenat Diagn* 2018; **38**: 951–957.
76. Bravo C, Gámez F, Pérez R, Álvarez T, De León-Luis J. Fetal Aortic Arch Anomalies: Key Sonographic Views for Their Differential Diagnosis and Clinical Implications Using the Cardiovascular System Sonographic Evaluation Protocol. *J Ultrasound Med* 2016; **35**: 237–251.
77. Anton T, Sklansky MS, Perez M, Pretorius DH. The Fetal 3-Vessel Views: An Illustrative Case-Based Tutorial. *J Ultrasound Med* 2019; **38**: 3335–3347.
78. Bronshtein M, Gover A, Zimmer EZ. Sonographic definition of the fetal situs. *Obstet Gynecol* 2002; **99**: 1129–1130.
79. Slotnick RN, Abuhamad AZ. Prognostic implications of fetal echogenic bowel. *Lancet Lond Engl* 1996; **347**: 85–87.
80. Sairam S, Al-Habib A, Sasson S, Thilaganathan B. Natural history of fetal hydronephrosis diagnosed on mid-trimester ultrasound. *Ultrasound Obstet Gynecol* 2001; **17**: 191–196.
81. Nguyen HT, Benson CB, Bromley B, Campbell JB, Chow J, Coleman B, Cooper C, Crino J, Darge K, Herndon CDA, Odibo AO, Somers MJG, Stein DR. Multidisciplinary consensus on the classification of prenatal and postnatal urinary tract dilation (UTD classification system). *J Pediatr Urol* 2014; **10**: 982–998.
82. Fontanella F, Groen H, Duin LK, Suresh S, Bilardo CM. Z-scores of fetal bladder size for antenatal differential diagnosis between posterior urethral valves and urethral atresia. *Ultrasound Obstet Gynecol* 2021; **58**: 875–881.
83. Van den Hof MC, Nicolaidis KH, Campbell J, Campbell S. Evaluation of the lemon and banana signs in one hundred thirty fetuses with open spina bifida. *Am J Obstet Gynecol* 1990; **162**: 322–327.
84. Dighe M, Fligner C, Cheng E, Warren B, Dubinsky T. Fetal skeletal dysplasia: an approach to diagnosis with illustrative cases. *Radiogr Rev Publ Radiol Soc N Am Inc* 2008; **28**: 1061–1077.
85. Chitty LS, Altman DG. Charts of fetal size: limb bones. *BJOG* 2002; **109**: 919–929.
86. Kumar M, Thakur S, Haldar A, Anand R. Approach to the diagnosis of skeletal dysplasias: Experience at a center with limited resources. *J Clin Ultrasound JCU* 2016; **44**: 529–539.
87. Jaumiaux E, Alfirevic Z, Bhide AG, Belfort MA, Burton GJ, Collins SL, Dornan S, Jurkovic D, Kayem G, Kingdom J, Silver R, Sentilhes L, Royal College of Obstetricians and Gynaecologists. Placenta Praevia and Placenta Accreta: Diagnosis and Management: Green-top Guideline No. 27a. *BJOG* 2019; **126**: e1–e48.

88. Jauniaux E, Alfirevic Z, Bhide AG, Burton GJ, Collins SL, Silver R, Royal College of Obstetricians and Gynaecologists. Vasa Praevia: Diagnosis and Management: Green-top Guideline No. 27b. *BJOG* 2019; **126**: e49–e61.
89. Jain V, Bos H, Bujold E. Guideline No. 402: Diagnosis and Management of Placenta Previa. *J Obstet Gynaecol Can* 2020; **42**: 906–917.e1.
90. Jansen CHJR, Kleinrouweler CE, van Leeuwen L, Ruiters L, Limpens J, van Wely M, Mol BW, Pajkrt E. Final outcome of a second trimester low-positioned placenta: A systematic review and meta-analysis. *Eur J Obstet Gynecol Reprod Biol* 2019; **240**: 197–204.
91. Jansen CHJR, Kleinrouweler CE, Kastelein AW, Ruiters L, van Leeuwen E, Mol BW, Pajkrt E. Follow-up ultrasound in second-trimester low-positioned anterior and posterior placentae: prospective cohort study. *Ultrasound Obstet Gynecol* 2020; **56**: 725–731.
92. Oppenheimer L. Diagnosis and management of placenta previa. *J Obstet Gynaecol Can* 2007; **29**: 261–273.
93. Collins SL, Ashcroft A, Braun T, Calda P, Langhoff-Roos J, Morel O, Stefanovic V, Tutschek B, Chantraine F, European Working Group on Abnormally Invasive Placenta (EW-AIP). Proposal for standardized ultrasound descriptors of abnormally invasive placenta (AIP). *Ultrasound Obstet Gynecol* 2016; **47**: 271–275.
94. Jauniaux E, Bhide A, Kennedy A, Woodward P, Hubinont C, Collins S, FIGO Placenta Accreta Diagnosis and Management Expert Consensus Panel. FIGO consensus guidelines on placenta accreta spectrum disorders: Prenatal diagnosis and screening. *Int J Gynaecol Obstet* 2018; **140**: 274–280.
95. Ruiters L, Kok N, Limpens J, Derks JB, de Graaf IM, Mol B, Pajkrt E. Incidence of and risk indicators for vasa praevia: a systematic review. *BJOG* 2016; **123**: 1278–1287.
96. Zhang W, Geris S, Al-Emara N, Ramadan G, Sotiriadis A, Akolekar R. Perinatal outcome of pregnancies with prenatal diagnosis of vasa praevia: systematic review and meta-analysis. *Ultrasound Obstet Gynecol* 2021; **57**: 710–719.
97. Lee W, Lee VL, Kirk JS, Sloan CT, Smith RS, Comstock CH. Vasa praevia: prenatal diagnosis, natural evolution, and clinical outcome. *Obstet Gynecol* 2000; **95**: 572–576.
98. Ranzini AC, Oyelese Y. How to screen for vasa praevia. *Ultrasound Obstet Gynecol* 2021; **57**: 720–725.
99. Conde-Agudelo A, Romero R, Da Fonseca E, O'Brien JM, Cetingoz E, Creasy GW, Hassan SS, Erez O, Pacora P, Nicolaides KH. Vaginal progesterone is as effective as cervical cerclage to prevent preterm birth in women with a singleton gestation, previous spontaneous preterm birth, and a short cervix: updated indirect comparison meta-analysis. *Am J Obstet Gynecol* 2018; **219**: 10–25.
100. Romero R, Conde-Agudelo A, Da Fonseca E, O'Brien JM, Cetingoz E, Creasy GW, Hassan SS, Nicolaides KH. Vaginal progesterone for preventing preterm birth and adverse perinatal outcomes in singleton gestations with a short cervix: a meta-analysis of individual patient data. *Am J Obstet Gynecol* 2018; **218**: 161–180.
101. Hassan SS, Romero R, Vidyadhari D, Fusey S, Baxter JK, Khandelwal M, Vijayaraghavan J, Trivedi Y, Soma-Pillay P, Sambarey P, Dayal A, Potapov V, O'Brien J, Astakhov V, Yuzko O, Kinzler W, Dattel B, Sehdev H, Mazheika L, Manchulenko D, Gervasi MT, Sullivan L, Conde-Agudelo A, Phillips JA, Creasy GW, PREGNANT Trial. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: a multicenter, randomized, double-blind, placebo-controlled trial. *Ultrasound Obstet Gynecol* 2011; **38**: 18–31.
102. Wikström T, Kuusela P, Jacobsson B, Hagberg H, Lindgren P, Svensson M, Wennerholm UB, Valentin L. Cost-effectiveness of cervical length screening and progesterone treatment to prevent spontaneous preterm delivery in Sweden. *Ultrasound Obstet Gynecol* 2022; **59**: 778–792.
103. Werner EF, Hamel MS, Orzechowski K, Berghella V, Thung SF. Cost-effectiveness of transvaginal ultrasound cervical length screening in singletons without a prior preterm birth: an update. *Am J Obstet Gynecol* 2015; **213**: 554.e1–6.
104. Society for Maternal-Fetal Medicine Publications Committee, with assistance of Vincenzo Berghella. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. *Am J Obstet Gynecol* 2012; **206**: 376–386.
105. Committee on Practice Bulletins—Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth. *Obstet Gynecol* 2012; **120**: 964–973.
106. Khalifeh A, Berghella V. Universal cervical length screening in singleton gestations without a previous preterm birth: ten reasons why it should be implemented. *Am J Obstet Gynecol* 2016; **214**: 603.e1–5.
107. Berghella V. Cerclage decreases preterm birth: finally the level I evidence is here. *Am J Obstet Gynecol* 2011; **205**: 89–90.
108. Medley N, Poljak B, Mammarella S, Alfirevic Z. Clinical guidelines for prevention and management of preterm birth: a systematic review. *BJOG* 2018; **125**: 1361–1369.
109. *Preterm Labour and Birth*. NICE Guideline, No. 25. National Institute for Health and Care Excellence: London; 2019.

APPENDICES

Appendix 1 Grades of recommendation and levels of evidence used in ISUOG Guidelines

Classification of evidence levels

1++	High-quality meta-analyses, systematic reviews of randomized controlled trials or randomized controlled trials with very low risk of bias
1+	Well-conducted meta-analyses, systematic reviews of randomized controlled trials or randomized controlled trials with low risk of bias
1–	Meta-analyses, systematic reviews of randomized controlled trials or randomized controlled trials with high risk of bias
2++	High-quality systematic reviews of case–control or cohort studies or high-quality case–control or cohort studies with very low risk of confounding, bias or chance and high probability that the relationship is causal
2+	Well-conducted case–control or cohort studies with low risk of confounding, bias or chance and moderate probability that the relationship is causal
2–	Case–control or cohort studies with high risk of confounding, bias or chance and significant risk that the relationship is not causal
3	Non-analytical studies, e.g. case reports, case series
4	Expert opinion

Grades of recommendation

A	At least one meta-analysis, systematic review or randomized controlled trial rated as 1++ and applicable directly to the target population; or a systematic review of randomized controlled trials or a body of evidence consisting principally of studies rated as 1+ applicable directly to the target population and demonstrating overall consistency of results
B	Body of evidence including studies rated as 2++ applicable directly to the target population and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+
C	Body of evidence including studies rated as 2+ applicable directly to the target population and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2++
D	Evidence level 3 or 4; or evidence extrapolated from studies rated as 2+
Good practice point	Recommended best practice based on the clinical experience of the guideline development group

